Search PubMedSearch

Biomedical subjects

M Baumstark

Publications and source records attributed to M Baumstark.

3 recordsLinked to original sources

[Doping--also a problem in general practice?].

In 1986, the Medical Commission of the IOC defined doping as the use of pharmacological substances belonging to disallowed groups of active substances (stimulants, narcotics, anabolic steroids, beta-blockers, diuretics). With certain restrictions, this applies also to alcohol, local anesthetics and corticosteroids. The use of disallowed methods (blood doping, manipulation of a urine sample) is also forbidden. These days the greatest importance is attached to anabolic steroids (including testosterone), since these substances--discontinued in good time--cannot be detected on the day of competition but still have a promoting effect on performance. Competitive sports prepared the way here for the use of anabolic steroids in general athletics and in particular usually non-olympic sports (such as bodybuilding). Against this background, effects, adverse effects and the risks of anabolic steroid use are discussed. The aim must be to prevent the use of doping, especially in uncontrollable general sports, by promoting proper awareness.

Anabolic Agents

Influence of probucol administration on lipoprotein cholesterol and apolipoproteins in normolipemic males.

In order to interpret the known lipoprotein changes in probucol-treated patients, serum concentrations of apolipoproteins (A-I, A-II, B, C-II, C-III, E) were measured before, during and after probucol administration (2 X 500 mg p.d.), in 16 healthy males (30.3 +/- 5.6 years old). Cholesterol concentrations were determined in LDL and VLDL fractions as well as in HDL subfractions which were isolated by preparative ultracentrifugation. In addition, apolipoprotein A-I and A-II concentrations were measured in the HDL subfractions. Compared with the baseline values, significant apolipoprotein changes were found in the serum apolipoprotein A-I (151 +/- 18 to 115 +/- 31 mg/dl; P less than 0.001) and C-II levels during administration. The HDL subfraction analysis showed that the decrease of HDL-cholesterol and apolipoprotein A-I (59.9 +/- 23.5 to 34.4 +/- 16.4 mg/dl, P less than 0.001, and 65.7 +/- 49.0 to 37.5 +/- 23.5 mg/dl, P less than 0.05, respectively) was predominantly related to the HDL2b subfraction (d = 1.063-1.100 g/ml).

Adult